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Abstract
L-Arginine is considered as a non-essential amino acid for most adult mammalian species, but it is
classiﬁed as essential for birds, ﬁsh, possibly reptiles and also for strict carnivores. L-Arginine produced by
fermentation with Escherichia coli NITE BP-02186, genetically modiﬁed to enhance the production of
L-arginine, is intended to be used in feed and water for drinking for all animal species and categories. The
product under assessment does not give rise to any safety concern with regard to the genetic
modiﬁcation of the production strain. Its use as a nutritional additive is safe for target species when
supplemented to diets in appropriate amounts. The use of L-arginine as a feed ﬂavouring agent is unlikely
to pose any concern. No risks are expected for the consumer from the use of the product under
assessment as a feed additive. It is not irritant to skin or eyes, nor a skin sensitiser. Although the presence
of endotoxin activity is of no concern, the available exposure and toxicological data indicate that the
additive may pose a risk to users by inhalation. The use of this additive in animal nutrition does not pose a
risk to the environment. The additive is an effective source of arginine for all species. L-Arginine is
considered efﬁcacious when used as a ﬂavouring compound in animal nutrition.
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Summary
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on L-arginine
produced by fermentation with Escherichia coli NITE BP-02186 when used as nutritional additive and
sensory additive for all animal species.
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of L-arginine was
in line with the principles laid down in Regulation (EC) No 429/2008 and the relevant EFSA guidance
documents. The FEEDAP Panel used the data provided by the applicant together with data from other
sources, such as previous risk assessments by the European Food Safety Authority (EFSA) or other
expert bodies, peer-reviewed scientiﬁc papers, other scientiﬁc reports and experts’ knowledge, to
deliver the present output.
L-Arginine is considered as a non-essential amino acid for most adult mammalian species, but it is
classiﬁed as essential for birds, ﬁsh, possibly reptiles and also for strict carnivores.
Neither the production strain E. coli NITE BP-02186 nor its recombinant DNA was detected in the
ﬁnal product. The product L-arginine, manufactured by fermentation with E. coli NITE BP-02186, does
not give rise to any safety concern with regard to the genetic modiﬁcation of the production strain.
The use of L-arginine produced by E. coli NITE BP-02186 as a nutritional additive is safe for target
species when supplemented to diets in appropriate amounts. There are no safety concerns arising
from ruminal L-arginine metabolism. The use of L-arginine as a feed ﬂavouring agent is unlikely to pose
any concern.
No risks are expected for the consumer from the use of L-arginine produced by E. coli NITE
BP-02186 as a feed additive.
The product under assessment is not irritant to skin or eyes, nor a skin sensitiser. Although the
presence of endotoxin activity is of no concern, the available exposure and toxicological data indicate
that the additive may pose a risk to users by inhalation.
The use of the product under assessment in animal nutrition does not pose a risk to the
environment.
The additive is an effective source of the amino acid arginine for all species. For the supplemental
L-arginine to be as efﬁcacious in ruminants as in non-ruminant species, it requires protection against
microbial degradation in the rumen. L-Arginine is considered efﬁcacious when used as a ﬂavouring
compound in animal nutrition.
The FEEDAP Panel made a recommendation concerning the description of the additive.
L-Arginine produced by Escherichia coli for all animal species
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission received a request from Ajinomoto Eurolysine S.A.S.2 for authorisation of
the product L-arginine, feed grade when used as a feed additive for all animal species. The application is
for use in feed and in water for drinking. Two different uses of the additive are proposed: (i) under
category: nutritional additives; functional group: amino acids, their salts and analogues and (ii) under
category: sensory additives; functional group: ﬂavouring compounds.
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 4(1)
(authorisation of a feed additive or new use of a feed additive). The particulars and documents in
support of the application were considered valid by EFSA as of 18 July 2017.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of the
product L-arginine, when used under the proposed conditions of use (see Section 3.1.7).
1.2. Additional information
The product L-arginine, feed grade, produced by the genetically modiﬁed strain of Escherichia coli
NITE BP-02186 has not been previously authorised as a feed additive in the European Union (EU).
L-Arginine (98%) produced by Corynebacterium glutamicum strains ATCC 13870, KCTC 10423BP or
KCCM 80099 is currently authorised as a nutritional feed additive for all animals without any restrictions by
Commission Regulation (EC) No 1139/20073 and Commission Implementing Regulation (EU) 2016/9724,
respectively.
The EFSA Scientiﬁc Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)
issued three opinions on the safety and efﬁcacy of the product containing L-arginine produced by
fermentation using C. glutamicum (strains ATCC 13870, KCTC 10423BP or KCCM 80099, respectively) for
all animal species (EFSA, 2007; EFSA FEEDAP Panel, 2016, 2017). The FEEDAP Panel issued one opinion
on the safety and efﬁcacy of the use of amino acids (chemical group 34) when used as ﬂavourings for all
animal species (EFSA FEEDAP Panel, 2014).
The EU Scientiﬁc Committee for Food (SCF) found acceptable the use of L-arginine as a food for
particular nutritional purposes (European Commission, 1999). The Joint FAO/WHO Expert Committee
on Food Additives (JECFA) issued an opinion on the safety evaluation of certain food additives
prepared by the sixty-third meeting of this committee (WHO, 2006) that included L-arginine.
The EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA Panel) delivered two opinions
related to the substantiation of health claims related to L-arginine (EFSA NDA Panel, 2011a,b).
L-Arginine, like other amino acids and other nitrogen compounds, is authorised for food use
according to Commission Regulation (EC) No 1243/2008 for infant formulae and follow-on formulae.5
According to Commission Regulation (EC) No 953/2009 and Commission Directive 2001/15/EC, amino
acids such as L-arginine may be added in all dietary foods for particular nutritional uses including foods
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 Ajinomoto Eurolysine S.A.S,153 rue de Courcelles, 75817 Paris Cedex 17, France.
3 Commission Regulation (EC) No 1139/2007 of 1 October 2007 concerning the authorisation of l-arginine as a feed additive. OJ
L 256, 11, 2.10.2007, p. 3.
4 Commission Implementing regulation (EU) 2016/972 of 17 June 2016 concerning the authorisation of L-arginine produced by
Corynebacterium glutamicum KCTC 10423BP as feed additive for all animal species. OJ L 161/18, 18.6.2016, p. 3.
5 Commission Regulation (EC) No 1243/2008 of 12 December 2008 amending Annexes III and VI to Directive 2006/141/EC as
regards compositional requirements for certain infant formulae. OJ L 335 25, 13.12.2008, p. 18.
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for particular nutritional uses intended for special medical purposes.6 L-Arginine and related compounds
are also registered as an ingredient in cosmetic products (Commission Decision 2006/257/EEC).7
L-Arginine is registered as pharmaceutical grade (for total parenteral nutrition) in many European countries
and is described in a monograph of the European Pharmacopoeia (European Pharmacopoeia, 2014).
According to Commission Regulation (EU) No 37/2010, L-arginine is also listed as pharmacologically active
substance in veterinary medicinal products and is not subjected to maximum residue levels when used in
food producing animals.8
A risk assessment has been made for L-arginine in food (Shao and Hathcock, 2008); the authors
concluded that arginine at intakes up to 20 g/day was safe for normal healthy adults.
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier9 in support of the authorisation request for the use of L-arginine, feed grade, produced by
E. coli NITE BP-02186 as a feed additive (nutritional and sensory) for feed and water for drinking. The
technical dossier was prepared following the provisions of Article 7 of Regulation (EC) No 1831/2003,
Regulation (EC) No 429/200810 and the applicable EFSA guidance documents.
The FEEDAP Panel used the data provided by the applicant together with data from other sources,
such as previous risk assessments by EFSA or other expert bodies, peer-reviewed scientiﬁc papers,
other scientiﬁc reports and experts’ knowledge, to deliver the present output.
EFSA has veriﬁed the European Union Reference Laboratory (EURL) report as it relates to the
methods used for the control of L-arginine in animal feed. The Executive Summary of the EURL report
can be found in Annex A.11
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of L-arginine,
feed grade, is in line with the principles laid down in Regulation (EC) No 429/2008 and the relevant
guidance documents: Guidance on nutritional additives (EFSA FEEDAP Panel, 2012a), Guidance for the
preparation of dossiers for sensory additives (EFSA FEEDAP Panel, 2012b), Technical guidance:
Tolerance and efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011), Technical Guidance for
assessing the safety of feed additives for the environment (EFSA, 2008a), Guidance for establishing
the safety of additives for the consumer (EFSA FEEDAP Panel, 2012c), Guidance on studies concerning
the safety of use of the additive for users/workers (EFSA FEEDAP Panel, 2012d), Technical Guidance:
Microbial Studies (EFSA, 2008b), Guidance on the assessment of bacterial susceptibility to
antimicrobials of human and veterinary importance (EFSA FEEDAP Panel, 2012e), Guidance for the
preparation of dossiers for additives already authorised for use in food (EFSA FEEDAP Panel, 2012f)
and Guidance on the risk assessment of genetically modiﬁed microorganisms and their products
intended for food and feed use (EFSA GMO Panel, 2011).
3. Assessment
The product subject of this application is L-arginine (≥ 98% on dry matter basis) produced by
fermentation with a genetically modiﬁed strain of E. coli K-12. It is intended for use in feed and water
for drinking for all animal species and categories, under the category 3c of Regulation EC 1831/2003
6 Commission Directive 2001/15/EC of 15 February 2001 on substances that may be added for speciﬁc nutritional purposes in
foods for particular nutritional uses. OJ L 52, 22.2.2001, pp. 19–25. Commission Regulation (EC) No 953/2009 of 13 October
2009 on substances that may be added for speciﬁc nutritional purposes in foods for particular nutritional uses. OJ L 269 9,
14.10.2009, 11 pp.
7 Commission Decision of 9 February 2006 amending Decision 96/335/EC establishing an inventory and a common
nomenclature of ingredients employed in cosmetic products. OJ L 97, 5.4.2006, pp. 1–528.
8 Commission Regulation (EU) No 37/2010, of 22 December 2009 on pharmacologically active substances and their classiﬁcation
regarding maximum residue limits in foodstuffs of animal origin. OJ L 15, 20.1.2010, pp. 72.
9 FEED dossier reference: FAD-2017-0028.
10 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
11 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/jrcsh/files/ﬁnrep_fad-2017-0028_arginine.pdf
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‘amino acids, their salts and analogues’; and the category 2.b ‘ﬂavouring compounds’. Although
authorisation is sought for these two classiﬁcations, the additive is strictly identical, with the same
characterisation and manufacturing process. The present assessment will follow the structure of the
nutritional additives’ scientiﬁc opinions and will incorporate, when needed, the corresponding sections
for sensory additives (ﬂavouring compounds).
L-Arginine is considered as a non-essential amino acid for most adult mammalian species including
humans, but it is classiﬁed as essential for birds, ﬁsh, possibly reptiles and also for strict carnivores.
For mammalian neonates, it is also considered to be essential.
3.1. Characterisation
3.1.1. Characterisation of the active substance
L-Arginine (International Union of Pure and Applied Chemistry (IUPAC) name: (S)-2-amino-5-
guanidinopentanoic acid; synonym 2-amino-5-guanidinovaleric acid), is a compound identiﬁed with the
Chemical Abstracts Service (CAS) No 74-79-3, and the European Inventory of Existing Commercial
chemical Substances (EINECS) No 200-811-1). It has a molecular mass of 174.2 Da. The molecular
formula of L-arginine is C6H14N4O2. The structural formula is given in Figure 1.
3.1.2. Characterisation of the production organism
The additive is produced by a genetically modiﬁed strain of E. coli K-12 (AJ111230), which is
deposited in the National Institute of Technology and Evaluation (NITE) of Japan with accession number
NITE BP-02186.12 The strain was identiﬁed as E. coli K-12 by biochemical tests, molecular serotyping
and multilocus sequence typing (MLST) using data obtained by whole genome sequence (WGS).13
E. coli NITE BP-02186 was tested for antibiotic susceptibility using culture broth suspension
microdilution. The battery of antibiotics tested was that recommended by EFSA (EFSA FEEDAP Panel,
2012a–f) for E. coli. All minimum inhibitory concentration (MIC) values were below the corresponding
cut-off values deﬁned by the FEEDAP Panel. In addition, no acquired antimicrobial resistance genes
were found by searching the WGS against relevant databases.13 WGS analysis also indicated the
absence of known E. coli virulence factors, including genes encoding enterotoxins, shiga toxins,
adhesion and invasion factors.13
3.1.2.1. Information relating to the genetically modiﬁed microorganism
Characteristics of the recipient or parental microorganism
The recipient strain is E. coli K-12S B-7, derivative of E. coli K-12 obtained by conventional
mutagenesis (UV irradiation). E. coli K-12 is well-characterised and its safety (non-pathogenicity) has
been documented extensively (Gorbach, 1978). Its genome is fully sequenced (Hayashi et al., 2006).
Characterisation of the donor organism
.
Figure 1: Molecular structure of L-arginine
12 Technical dossier/Section II/Annex Supp II.1.1 Deposition Certiﬁcate NITE BP-02186.
13 Technical dossier/Section II/Annex Supp II.6.
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3.1.2.2. Description of the genetic modiﬁcation
The objective of the genetic modiﬁcation was to increase the production of L-arginine in E. coli strain
. The genes of interest were
.
The strain K-12S B-7 was modiﬁed to obtain the production strain E. coli
NITE BP-02186:
As a result of the genetic modiﬁcations,
During the genetic modiﬁcation processes to construct the production strain NITE BP-02186,
The absence of all full-
length antibiotic resistance genes used during the genetic modiﬁcation from the ﬁnal production strain was
demonstrated by Southern analysis14 and comparison of the WGS with relevant databases.15
. The production strain was susceptible to all of the antibiotics involved.
3.1.3. Manufacturing process
L-Arginine is produced in a fed-batch fermentation process with E. coli NITE BP-02186. After
fermentation, the fermentation broth is inactivated
The fermentation medium contains
16
No antibiotic is used during fermentation process.17
14 Technical dossier//Section II/Annex_Supp_II_38.
15 Technical dossier/Section II/Annex_Supp_II_6.
16
17 Technical dossier/Section II.2.3.1.2.1.
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3.1.4. Characterisation of the additive
According to the speciﬁcation, the additive contains ≥ 98% L-arginine on dry matter basis. Other
components not quantiﬁed are moisture and other amino acids. The analysis of ﬁve industrial pilot
batches (from the ultimate phase of the manufacturing process development before routine industrial
implementation) showed an average value of L-arginine of 98.4% on ‘as is’ basis (range 98.1–98.8%).18
Moisture average was 0.9% (range 0.4–1.3%) and no quantiﬁable free amino acids other than arginine
could be detected. The content of arginine in the additive was 99.3% on dry matter basis (range
99.1–99.4). Sum of quantiﬁable ammonium, nitrates, nitrites and betaine was on average 0.33%
(0.21–0.44%). Sum of quantiﬁable organic acids was on average 0.2% (0.04–0.41%).19 Sum of
quantiﬁable inorganic cations and anions was on average 0.03% (0.02–0.03%).20 The amount of
identiﬁed material was 99.85% on dry matter basis.
Analytical data on speciﬁc optical rotation of three batches showed a range + 26.9° to + 27.0°,
which is within the range described in the European Pharmacopoeia for this amino acid (+ 25.5° to
+ 28.5°).21
3.1.4.1. Impurities
Three batches were analysed for impurities. Cadmium, lead, mercury and arsenic were below the
limit of detection (LOD).22 Other elements or compounds analysed were chromium, copper, nickel,
phosphorus and ﬂuorine (in ﬁve batches), and melamine and cyanic acid (in three batches), all them
with values below the respective LODs. Iron (analysed in ﬁve batches) ranged from below LOD to
0.2 mg/kg. The sum of dioxins (polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans
(PCDD/F)) and dioxin-like polychlorinated biphenyls (DL-PCBs) ranged from 0.0486 to 0.0542 ng WHO-
PCDD/F-PCB TEQ per kg (Van den Berg et al., 2006, upper limit). Non dioxin-like PCBs (IECS-6) ranged
from 0.051 to 0.067 ng/kg TEQ (Van den Berg et al., 2006, upper limit).23 Residues of organochlorine
(including pyrethroids) and organophosphorus pesticides (analysed in three batches) were all below
the limit of quantiﬁcation.24
The microbial analyses of six batches of the product showed the absence of Salmonella spp. (25 g
samples); total germ count (at 30°C) < 100 CFU/g; coliforms, Staphylococcus coagulase positive, yeast
and moulds < 10 CFU/g; and Bacillus cereus (at 30°C) < 100 CFU/g.25 As regards the mycotoxins,
analysis of three batches showed values of aﬂatoxins (B1, B2, G1, G2), zearalenone, deoxynivalenol,
ochratoxin A, T-2 and HT-2 toxins, fumonisins (B1, B2 and B3) below the respective limits of
quantiﬁcation (LOQ).26
Endotoxin activity was measured in three batches of the additive (Limulus amoebocyte lysate test)
and the values ranged from 0.4 to 2.9 IU/g.27
No viable cells of the production strain were found in three batches of the product (each tested in
triplicate). Tests were done by (i) ﬁltering 100 mL of a 10 g/L solution of the product and incubating the
ﬁlter on non-restrictive solid medium at 37°C for 2 days, and (ii) incubation of 1 g of product in non-
restrictive, liquid medium at 37°C for 3 days and subsequent plating in the same conditions as before.28
No recombinant DNA was detected in three batches of L-arginine by polymerase chain reaction
(PCR),
28
18 Technical dossier/Section II/Annex II.2.1 to II.2.5. Method derived from NF ISO 17180 expanded to arginine, see Annex II.4.
19 Technical dossier/Section 2.1.3.2.5. Organic acids analy sed were lactate, formiate, pyruvate, acetate, propionate, butyrate
and isovalerate.
20 Technical dossier/Section 2.1.3.2.6. Anions analysed were chlorides, sulphates and phosphates; cations analysed were
potassium, calcium, magnesium and sodium.
21 Technical dossier/Section II/Annex II.1.2.
22 Technical dossier/Section II/Annex II.9.1 to II.9.5. LOD in mg/kg was 0.005 for mercury; 0.05 for lead; 0.01 for cadmium; 0.1
for arsenic, copper, iron and nickel; 0.5 for melamine; 1.5 for hydrocyanic acid; 3 for phosphorous and 20 for ﬂuorine.
Chromium had three batches analysed with a LOD of 0.2 and other two batches with a LOD of 0.05.
23 Technical dossier/Section II/Annex II.9.1 to II.9.3.
24 Technical dossier/Section II/Annexes II.9.1 to II.9.3 and Annex II.10. LOQ in mg/kg for the 107 organochlored pesticides
(including pyrethroids) ranged from 0.002 to 0.01; and for the 116 organophosphorus pesticides ranged from 0.01 to 0.03.
25 Technical dossier/Section II/Annexes II.9.1 to II.9.3 and II.11.10 to II.11.12.
26 Technical dossier/Section II/Annex II.9.1 to II.9.3. LOQ in µg/kg was 0.1 for aﬂatoxins B1, B2 and G1; 0.2 for aﬂatoxin G2
and ochratoxin A; 20 for zearalenone, T2 and HT-2 toxins and the fumonisins; and 50 for deoxynivalenol.
27 Technical dossier/Section II/Annex II.16.
28
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The absence of antimicrobial activity of the production strain was investigated (three batches of the
additive) using the method described in EFSA ‘Technical Guidance on Microbial studies’.29 Antimicrobial
effect against one of the ﬁve strains (Pseudomonas aeruginosa ATCC 27853) was observed at a MIC of
9.1% after 24–48 h incubation at 37°C. The FEEDAP Panel considers that if a MIC is equal to or below
four times the maximum additive concentration in feed/water, there are no safety concerns. The
normal use level ranges from 0.01% to 0.2% arginine in feed. Four times the highest value of this
range is 0.8%, one order of magnitude below 9.1% and consequently the antimicrobial activity
observed does not raise safety concerns at normal use levels.
3.1.4.2. Physical characteristics
The additive is a white or pale yellow crystalline powder. Its solubility in water at 20°C is 148 g/L, it has
a pH ranging from 10.5 to 12.0 (5% solution in water),30 and its aerated bulk density is 590–662 kg/m3.31
The particle size distribution was analysed in ﬁve batches by laser diffraction (v/v) and the fractions
having diameters < 10, < 50 and < 100 lm were 0–0.4%, 0.2–2.5% and 1.2–5.6%, respectively.32
The applicant provided analytical data on dusting potential (Stauber–Heubach method) of four
batches of the additive and the results ranged from 0.41 to 1.71 g/m3.33 The applicant calculated the
dust fractions (inhalable, thoracic and respirable) of each batch. Inhalable fraction ranged from 0.30 to
1.27 g/m3; thoracic fraction from 0.13 to 0.64 g/m3 and the respirable fraction from 0.03 to 0.15 g/m3.
3.1.5. Stability and homogeneity
3.1.5.1. Shelf life
The shelf life of the additive (three batches) was studied when stored in closed plastic bottles at 25
and at 40°C during 12 months.34 No losses were observed.
3.1.5.2. Stability in premixtures
The stability of the additive (three batches) in three types of poultry premixtures (for layers and
starter and grower for chickens for fattening) was studied at 25°C and 30% relative humidity (RH) or at
40°C and 60% RH, when stored packed in sturdy nylon polyethylene (PE) bags punctured at the top (to
allow exchange of oxygen and humidity of the atmosphere) for 6 months.35 The supplemented levels in
the premixtures of layers, starter and grower for chickens for fattening were 2.2%, 2.1% and 2.7%
L-arginine, respectively. The premixtures contained vitamins and minerals, including choline chloride
(1.6–2% depending on the premixture). In premixtures stored at 25°C and 30% RH losses ranged from
0% to 1.5%. Losses in the premixtures stored at 40°C and 60% RH ranged from 15% to 23%.
3.1.5.3. Stability in feedingstuffs
The stability of the additive (three batches) in three types of poultry feeds (for layers (crumb), and
starter (mash) and grower (pelleted) feed for chickens for fattening) was studied at 25°C and 30%
relative humidity (RH) or at 40°C and 60% RH, when stored packed in sturdy nylon PE-bags punctured
at the top for 3 months.36 The basal diet was made of maize, wheat and soybean meal and the
supplemented levels in the compound feed of layers, starter and grower for chickens for fattening
were 0.09%, 0.11% and 0.14% L-arginine, respectively. In feeds stored at 25°C and 30% RH losses
ranged from 0% to 0.5%. In the feeds stored at 40°C and 60% RH, losses ranged from 6% to 15%.
The stability of the additive was studied during feed processing (pelleting consisting of pre-heating
mash at 60°C for 5 s, pelleting at 80°C for 1 s and cooling to ambient temperature in few minutes)
and no losses were observed.37
29 Technical dossier/Section II/Annex II.18.
30 Technical dossier/Section II/Annex II.13.
31 Technical dossier/Section II/Annex II.16 and supplementary information December 2017/Annex 2.
32 Technical dossier/Section II/Annex II.15.
33 Technical dossier/Supplementary information December 2017/Annex 2.
34 Technical dossier/Section II/Annex II.29.
35 Technical dossier/Section II/Annex II.31.
36 Technical dossier/Section II/Annex II.32.
37 Technical dossier/Supplementary information December 2017/Annex 3, table 4.3.
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3.1.5.4. Stability in water for drinking
The stability of the additive (three batches) in water for drinking was measured at 25°C when
diluted at 0.5, 2.5 and 5 g/L of local tap water.38 The solutions were stored in bottles up to 50 h. No
losses were observed.
3.1.5.5. Homogeneity
The capacity of the additive to distribute homogeneously in premixtures was studied in the poultry
premixtures described above.35 Ten subsamples of each premixture were analysed and the coefﬁcients
of variation (CV) ranged from 2.4% to 2.6%.
The capacity of the additive to distribute in feedingstuffs was studied in the poultry feeds described
above.36 Ten subsamples of each feed were analysed and the CVs ranged from 0.7% to 2.1%.
3.1.6. Physicochemical incompatibilities
No physicochemical incompatibilities are expected with other additives, medicinal products or the
components of feeds.
3.1.7. Conditions of use
As a nutritional additive, it is proposed that L-arginine will be used in feeds to achieve an adequate
amino acid proﬁle and to meet the L-arginine requirements for all animal species. It can be added
directly to feedingstuffs or complementary feedingstuffs, or via premixture. It is also proposed to use
the additive in water for drinking, either in addition to quantities provided by the feedingstuffs or in
place of these ones.39 No inclusion levels have been proposed, as the requirements, in quantitative
terms, depend on the species, the physiological state of the animal, the performance level, the
environmental conditions and the amino acid composition of the unsupplemented diet.
The applicant proposes a supplemental use in complete feedingstuffs ranging from 0.5 to 2 g
arginine/kg feed.40
As ﬂavouring compound, ﬂavouring premixtures can be added to mash feed or water for drinking,
or sprayed on pelleted or mash feed. Liquid ﬂavouring premixtures can be applied directly or after
dilution using an appropriate solvent. The applicant proposed a use up to the maximum concentration
of 25 mg/kg complete feed although in practice it is included at levels ranging from 0.1 to 2 mg/kg.39
No indications of the concentration used in water for drinking were given by the applicant.
3.2. Safety
3.2.1. Safety aspects of the genetic modiﬁcation41
The recipient organism E. coli K-12S B-7 is considered to be safe. The production strain NITE BP-02186
contains
. None of these introduced modiﬁcations raise a safety
concern. There are no genes in the ﬁnal production strain remaining from
the genetic modiﬁcation process.
The applicant provided sufﬁcient information that neither the production strain nor its recombinant
DNA is present in the ﬁnal product. The ﬁnal product, manufactured by fermentation with E. coli NITE
BP-02186, does not give rise to any safety concern with regard to the genetic modiﬁcation of the
production strain.
3.2.2. Safety for the target species
Tolerance studies with essential and conditionally essential amino acids cannot be designed in
accordance with the protocols of conventional toxicity experiments because high dietary concentrations
of a certain amino acid will result in amino acid imbalances and depression of feed intake and, hence,
impaired performance. This statement is, in principle, also applicable to non-essential amino acids
since a well-balanced dietary protein should have a certain ratio between essential and non-essential
38 Technical dossier/Section II/Annex II.33.
39 Technical dossier/Section II.2.5.1.
40 Technical dossier/Section IV/Section 4.2.
41 This section has been amended following the conﬁdentiality claims made by the applicant.
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amino acids for optimal performance and low nitrogen emissions per product (Baker, 2004). Nevertheless,
for nutritional additives produced by fermentation, the risks associated with the residues of the
fermentation process in the ﬁnal product need to be assessed. In this speciﬁc product, the purity is > 99%
and the amount of identiﬁed material represents > 99% on a dry matter basis. Therefore, the FEEDAP
Panel considers that safety concerns for target species are highly unlikely to arise from L-arginine
produced by E. coli NITE BP-02186.
The classiﬁcation of L-arginine as a dispensable or an indispensable amino acid, its dietary
requirements, the adverse effects of excess of arginine in the diets and the lysine-arginine antagonism
have been discussed in a previous opinion (EFSA FEEDAP Panel, 2016). In that opinion, it was reported
that feeding weaned piglets (age: 3–4 weeks; live weight 7 kg) in short-term experiments (3–4 weeks)
with 0.67%, 1.6% and 2.0% supplemental L-arginine decreased weight gain and feed intake, but had
variable effects on feed/gain and no effect on the nitrogen balance (Southern and Baker, 1982; Anderson
et al., 1984), whereas a moderate L-arginine supplementation (0.22%) did not affect performance of
growing piglets (Rosell and Zimmerman, 1983). More recent research (Hu et al., 2015; Wu et al., 2016),
however, revealed a higher tolerance to L-arginine in pig diets. The authors assessed the safety of long-
term L-arginine supplementation (0%, 1%, 1.5% and 2%) to a typical maize–soybean meal diet (1.35%
arginine as background) in pigs between 30 and 121 days of age, based on general observations (e.g.,
behaviour, skin health, and hair appearance), feed intake, growth, body composition, as well as
haematological and blood chemistry measurements. Results of all of the measured variables in the pigs
were within physiological ranges and were not adversely affected by the L-arginine supplementation.
In ruminants, arginine is extensively catabolised. The initial products of L-arginine degradation by
ruminal microorganisms are ornithine, d-aminovaleric acid, and putrescine (Lewis and Emery, 1962),
which are then either converted to volatile fatty acids or incorporated into microbial cell biomass. As
these products have no recorded deleterious effects to the host animal, there are no safety concerns
arising from ruminal L-arginine metabolism when supplemented to diets in appropriate amounts.
The use of L-arginine produced by E. coli NITE BP-02186 is safe for target species when supplemented
to diets in appropriate amounts. There are no safety concerns arising from ruminal L-arginine metabolism.
The applicant carried out a literature review and reports data on safety of arginine supplementation
in pigs for fattening, piglets, gestating sows, sheep and cattle, poultry, cats, dogs, rats and ﬁsh.42 The
data showed that (i) potential adverse effects may occur at high supplementation levels (usually
beyond a level of 2% arginine supplementation in the diet) and these may vary between and within
species; (ii) the observed adverse effects usually consist of reduced feed intake and weight gain.43
Although a study by Li et al. (2010) detected reduced embryonic survival and plasma progesterone in
sows during gestation at diets containing a total of 1.5% arginine in the diet (0.8% of which was
supplemented), other authors reported beneﬁcial effects on embryonic/foetal survival in sows and
survival of offspring with diets containing up to a total of 1.7% arginine in the diet (up to 1% of which
was supplemented) (Mateo et al., 2007, 2008; Li et al., 2015; Palencia et al., 2018). The FEEDAP
Panel notes that this literature review, while providing some additional information, does not modify
the previous assessments concerning arginine supplementation in target species (EFSA, 2007; EFSA
FEEDAP Panel, 2016, 2017).
The use of L-arginine as a feed ﬂavouring agent is proposed at the maximum level of 25 mg/kg
complete feed. The FEEDAP Panel considers that such inclusion level is unlikely to have any impact on
the arginine-lysine ratio when the amino acid composition of the diet is sufﬁciently balanced.
The FEEDAP Panel, in its previous statement (EFSA FEEDAP Panel, 2010), identiﬁed risks of
nutritional imbalances and hygienic concerns in amino acids when administered in water for drinking.
3.2.2.1. Conclusions on safety for the target species
The use of L-arginine produced by E. coli NITE BP-02186 at the doses proposed (0.5–2 g arginine/kg
feed) is safe for target species when supplemented to diets in appropriate amounts. There are no safety
concerns arising from ruminal L-arginine metabolism. The use of L-arginine as a feed ﬂavouring agent is
unlikely to pose any concern at the proposed maximum level of 25 mg/kg complete feed.
42 Technical dossier/Section III.3.1.1.
43 Technical dossier/Section III.3.1.1.2.
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3.2.3. Safety for the consumer
The absorption and metabolic fate of arginine were described in a previous opinion (EFSA, 2007).
As a general principle, conventional toxicology studies are considered to be inappropriate for amino
acids.
The product under assessment is produced by fermentation. Concerns for the consumer would
derive not from the amino acid itself, which will be incorporated into animal protein, but from possible
residues from the fermentation. Considering that the additive is highly puriﬁed (≥ 99% L-arginine on
dry matter basis), no additional toxicological data are required (EFSA FEEDAP Panel, 2012a–f).
Amino acids supplemented to feed will be incorporated into proteins of tissues and/or products of
target animal species and any of their potential excess will be metabolised and excreted. Therefore,
the composition of tissues and products of animal origin will not be changed by the use of L-arginine in
animal nutrition.
3.2.3.1. Conclusions on safety for the consumer
The composition of edible tissues and products of animal origin will not be changed by the use of
L-arginine in animal nutrition. Considering the high purity of the product under assessment, no risks
are expected for the consumer from the use of L-arginine produced by E. coli NITE BP-02186 as a feed
additive.
3.2.4. Safety for the user
The test item used in the following studies to support the safety for the user was the product
under assessment.
3.2.4.1. Effects on the respiratory system
The particle size and the dusting potential of the additive indicates that exposure by inhalation of
the user is likely (see Section 3.1.4.2).
An acute inhalation test was carried out with the additive under assessment on Crl:WI(Han) rats (ﬁve
males and ﬁve females) in accordance with OECD guideline 403.44 The FEEDAP Panel notes that the
batch used in this study had a lower potential for exposure of the respiratory system compared to other
batches of the additive (dusting potential 0.11 g/m3; no particles < 10 lm, 2.5% < 50 lm and 5.6% of
particles < 100 lm). After 4 h exposure at the dose of 5.1 g L-arginine/m3, some adverse effects were
observed: increased breathing rate during exposure in all animals, which resolved shortly after exposure
and sparse haired areas in two female rats which persisted up to the end of the post-treatment
observation period (14 days). At necropsy (performed 2 weeks after exposure), two out of ﬁve females
and four out of ﬁve males in the group exposed to L-arginine showed localised hyaline spots on the lungs
with partial collapse of the tissue in the affected region. In addition, one male had red spots in the
thymus. No such changes were present in the control group. Histopathology was not performed; based
on the data available, the observed changes should be regarded as treatment-related adverse effects
that can persist after a single exposure. The study design did not allow to set a no observed adverse
effects concentration (NOAEC). Considering the potential inhalation exposure and the observation of
persistent adverse effects, the FEEDAP Panel considers that the additive may pose a risk by inhalation.
The production species, E. coli, is a Gram-negative bacterium. Although the K-12 strain and its
derivatives are safe from the point of view of enterotoxins and other virulence factors (Gorbach, 1978;
EPA 1997, Bauer et al., 2007), E. coli K-12 retains lipopolysaccharide in its cell envelope (Luchi and
Morrison, 2000; Svensson et al., 2005; Gao et al., 2006) which potentially may result in endotoxin
activity in the ﬁnal product. Inhalation exposure to endotoxins is a concern for user safety (Rylander,
1999; Thorn, 2001). The scenario used to estimate the exposure of persons handling the additive to
endotoxins in the dust, based on the EFSA Guidance on user safety (EFSA FEEDAP Panel, 2012b) is
described in the Appendix A. The health based recommended threshold for the quantity of inhaled
endotoxins per working day is 900 IU, derived from provisional occupational exposure limits given by
the Dutch Expert Committee on Occupational Safety (DECOS) (Health Council of the Netherlands,
2010) and the UK Health and Safety Executive (HSE, 2013). Based upon the calculation of the
potential endotoxin content in dust, the inhalation exposure could be up to 2.75 endotoxin IU per
working day, indicating no risk of exposure to endotoxins for persons handling the additive.
44 Technical dossier/Section III/Annex III.3.159.
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3.2.4.2. Effects on skin and eyes
The additive under assessment has a high pH (10.5–12) in aqueous solution.
In an in vitro dermal irritation test based on reconstructed skin membranes in accordance with
OECD Guideline 439, the skin membranes were topically exposed to the additive under assessment for
60 min. Viability of the epidermal cells was assessed using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) test 43 h after exposure. The positive and negative controls performed
as expected. The mean viability of the skin membranes was 78% compared to the negative control
group.45 The additive was considered not irritant for the skin.
In an acute eye irritation study using the isolated chicken eye test in accordance with OECD 438,
30 mg of the product under assessment were applied for 10 s to chicken eyes, followed by a 20 mL
saline rinse. The eyes were examined periodically up to 240 min after exposure. Corneal swelling and
corneal opacity were very slight and ﬂuorescein retention slight to moderate. At microscopic
evaluation, only very slight vacuolation was observed in the top layer of the corneal epithelium. The
product was considered not irritant for the eye.
In a skin sensitisation study using local lymph node assay in the mouse, in accordance with OECD
Guideline 439, the product under assessment was tested topically at 10, 25 or 50% w/w (25 lL/ear).
All auricular lymph nodes of the animals of the experimental and control groups were considered
normal size. Since the test item elicited a stimulation index < 3 when tested up to 50%, the additive
was not considered to be a skin sensitiser.46
3.2.4.3. Conclusions on safety for the user
L-Arginine produced by E. coli NITE BP-02186 is not irritant to skin or eyes, nor a skin sensitiser.
Although the presence of endotoxin activity is of no concern, the available exposure and toxicological
data indicate that the additive may pose a risk to users by inhalation.
3.2.5. Safety for the environment
Neither the production strain E. coli NITE BP-02186 nor its recombinant DNA was detected in the
ﬁnal product. The ﬁnal product does not pose any environmental safety concern associated with the
genetic modiﬁcation of the production strain.
L-Arginine is a natural component of animals and plants whose use in animal nutrition would not
lead to any localised increase of its concentration in the environment. It is mainly not excreted as
such, but as urea or uric acid and carbon dioxide. The FEEDAP Panel concludes that the use of the
product L-arginine produced by E. coli NITE BP-02186 in animal nutrition would not pose a risk to the
environment.
3.3. Efﬁcacy
Efﬁcacy studies are not required for amino acids naturally occurring in proteins of plants and
animals. The nutritional role of the amino acid L-arginine is well established in the scientiﬁc literature.
Since L-arginine is used in food as ﬂavouring,47 it is to be expected that it can provide a similar
function in feed. Therefore, no further demonstration of efﬁcacy is necessary when used at
concentrations up to 25 mg/kg complete feed.
3.4. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation48 and Good
Manufacturing Practice.
45 Technical dossier/Section III/Annex III.168.
46 Technical dossier/Section III/Annex III.169.
47
L-Arginine (FL No 17.003) is included in the ‘Union list of ﬂavourings and source materials,’ Annex I of Regulation (EC) No
1334/2008 on ﬂavourings for use in and on foods.
48 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for
feed hygiene. OJ L 35, 8.2.2005, p. 1.
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4. Conclusions
Neither the production strain E. coli NITE BP-02186 nor its recombinant DNA was detected in the
ﬁnal product. The product L-arginine, manufactured by fermentation with E. coli NITE BP-02186, does
not give rise to any safety concern with regard to the genetic modiﬁcation of the production strain.
The use of L-arginine produced by E. coli NITE BP-02186 as a nutritional additive is safe for target
species when supplemented to diets in appropriate amounts. There are no safety concerns arising
from ruminal L-arginine metabolism. The use of L-arginine as a feed ﬂavouring agent is unlikely to pose
any concern.
No risks are expected for the consumer from the use of L-arginine produced by E. coli NITE BP-02186
as a feed additive.
The product under assessment is not irritant to skin or eyes, nor a skin sensitiser. Although the
presence of endotoxins is of no concern, the available exposure and toxicological data indicate that the
additive may pose a risk to users by inhalation.
The use of the product under assessment in animal nutrition does not pose a risk to the
environment.
The additive is an effective source of arginine for all species. L-Arginine is considered efﬁcacious
when used as a ﬂavouring compound in animal nutrition.
5. Recommendations
The description of the additive should contain the statement ‘L-arginine produced by Escherichia coli
NITE BP-02186’.
Documentation provided to EFSA
1) L-Arginine produced using strain NITE BP-02186. June 2017. Submitted by Ajinomoto
Eurolysine SAS.
2) L-Arginine produced using strain NITE BP-02186. Supplementary information. December
2017. Submitted by Ajinomoto Eurolysine SAS.
3) Evaluation report of the European Union Reference Laboratory for Feed Additives on the
Methods(s) of Analysis for L-arginine produced by fermentation with Escherichia coli NITE
BP-02186.
4) Comments from Member States.
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L-Arginine produced by Escherichia coli for all animal species
www.efsa.europa.eu/efsajournal 18 EFSA Journal 2018;16(5):5276
Appendix A – Safety for the user
The effects of endotoxin inhalation and the exposure limits have been described in a previous
opinion (EFSA FEEDAP Panel, 2015).
Calculation of maximum acceptable levels of exposure from feed additives
The probable exposure time according to EFSA guidance (EFSA FEEDAP Panel, 2012d) for additives
added in premixtures assumes a maximum of 40 periods of exposure per day, each comprising
20 s = 40 9 20 = 800 s/day. With an uncertainty factor of 2, maximum inhalation exposure would
occur for 2 9 800 = 1,600 s = 0.444 h/day. Again, assuming a respiration volume of 1.25 m3/h, the
inhalation volume providing exposure to potentially endotoxin-containing dust would be 0.444 9 1.25
= 0.556 m3/day. This volume should contain no more than 900 IU endotoxin, so the dust formed from
the product should contain no more than 900/0.556 = 1,619 IU/m3.
Calculation of endotoxin content of dust
Two key measurements are required to evaluate the potential respiratory hazard associated with
the endotoxin content of the product (the dusting potential of the product, expressed in g/m3, and the
endotoxin activity of the dust, determined by the Limulus amoebocyte lysate assay (expressed in
IU/g)). If data for the dust are not available, the content of endotoxins of the product can be taken
instead. If the content of endotoxins of the relevant additive is a IU/g and the dusting potential is
b g/m3, then the content of endotoxins of the dust, c IU/m3, is obtained by simple multiplication, a 9 b.
This resulting value is further used for calculation of the potential inhalatory exposure of users to
endotoxins from the additive under assessment (Table A.1) (EFSA FEEDAP Panel, 2012d).
Table A.1: Estimation of user exposure to endotoxins from the additive L-arginine produced by
Escherichia coli NITE BP-02186, including consideration of using a ﬁlter mask FF P2 or
FF P3 as a preventative measure
Calculation Identiﬁer Description Amount Source
a Endotoxin content IU/g product 2.9 Technical dossier
b Dusting potential (g/m3) 1.706 Technical dossier
a 9 b c Endotoxin content in the air (IU/m3) 4.95
d No of premixture batches made/
working day
40 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012d)
e Time of exposure (s) per production
of one batch
20 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012d)
d 9 e f Total duration of daily exposure/
worker (s)
800
g Uncertainty factor 2 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012d)
f 9 g h Reﬁned total duration of daily
exposure/worker (s)
1,600
h/3,600 i Reﬁned total duration of daily
exposure (h)
0.44
j Inhaled air (m3) per 8-h working day 10 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012d)
j/8 9 i k Inhaled air during exposure (m3) 0.56
c 9 k l Endotoxin inhaled (IU) during
exposure per 8-h working day
2.75
m Health-based recommended exposure
limit of endotoxin (IU/m3) per 8-h
working day
90 Health Council of the Netherlands
(2010)
m 9 j n Health-based recommended
exposure limit of total endotoxin
exposure (IU) per 8-h working
day
900
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Calculation Identiﬁer Description Amount Source
l/10 Endotoxins inhaled (IU) per 8-h
working day reduced by ﬁlter mask
FF P2 (reduction factor 10)
0
l/20 Endotoxins inhaled (IU) per 8-h
working day reduced by ﬁlter mask
FF P3 (reduction factor 20)
0
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Annex A – European Reference Laboratory evaluation report on the
analytical methods submitted with the application for authorisation of
L-arginine produced by fermentation with Escherichia coli NITE BP-02186
In the current application authorisation is sought under Article 4(1) for L-arginine produced by
fermentation with Escherichia coli NITE BP-02186, under the category/functional group 3(c) ‘nutritional
additives’/‘amino acids, their salts and analogues’ and 2(b) ‘sensory additives’/‘ﬂavouring compounds’,
according to Annex I of Regulation (EC) No 1831/2003. Authorisation is sought for all animal species.
L-arginine is already authorised as nutritional feed additive under Commission Regulation (EC)
No 1139/2007 and Commission Implementing Regulation (EU) 2016/972.
For the characterisation of the feed additive, the EURL identiﬁed the “L-arginine monograph” of the
Food Chemical Codex (FCC).
For the quantiﬁcation of arginine in the feed additive and premixtures, the Applicant submitted a
validated and further veriﬁed method derived from the ring trial validated method described in EN ISO
17180:2013. The method is based on ion exchange chromatography coupled with post-column
derivatisation and photometric detection (IEC-VIS). It is speciﬁcally intended for lysine, methionine and
threonine in commercial feed additives and premixtures. The method does not distinguish between the
salts of amino acids and it cannot differentiate between enantiomers. The corresponding method
performance characteristics, recalculated by the EURL from the experimental data provided, are in
agreement with those reported in the standard thus demonstrating the applicability of the slightly
modiﬁed protocol to the quantiﬁcation of arginine in the feed additive and premixtures.
For the quantiﬁcation of L-arginine in premixtures and feedingstuffs the Applicant submitted the
ring-trial validated Community method (Commission Regulation (EC) No 152/2009). The method was
further ring-trial validated by CEN resulting in EN ISO 13903:2005. The method is based on ion
exchange chromatography coupled with post-column derivatisation and photometric detection (IEC-
VIS). This method does not distinguish between the salts and the amino acid enantiomers. The
following performance characteristics were reported for the quantiﬁcation of total arginine: a relative
standard deviation for repeatability (RSDr) ranging from 2.3% to 3.3% and a relative standard
deviation for reproducibility (RSDR) ranging from 7.2% to 9.7%.
For the quantiﬁcation of L-arginine in water the Applicant suggested a procedure based on the
standard EN ISO 13903:2005. The Applicant did not perform a validation and veriﬁcation study, but
provided, in the frame of stability studies, the detailed experimental protocol used supported by
experimental data. From the data reported the EURL calculated the following performance
characteristics: RSDr ranging from 0.6% to 0.8% and relative standard deviation for intermediate
precision (RSDip) ranging from 0.6% to 1.0%. The performance characteristics obtained are in
agreement with those stated in the EN ISO 13903:2005 standard thus demonstrating the applicability
(extension of the scope) of the slightly modiﬁed protocol to the quantiﬁcation of arginine in water.
Based on the performance characteristics available, the EURL recommends for ofﬁcial control: (i) the
“L-arginine monograph” of the Food Chemical Codex (FCC) for the identiﬁcation of L-arginine in the feed
additive; (ii) the validated and further veriﬁed IEC-VIS analytical method for the quantiﬁcation of arginine
in the feed additive; (iii) the Community method based on IEC-VIS for the quantiﬁcation of arginine in
premixtures and feedingstuffs; and (iv) the IEC-VIS analytical method to quantify arginine in water.
Further testing or validation of the methods to be performed through the consortium of National
Reference Laboratories as speciﬁed by Article 10 (Commission Regulation (EC) No 378/2005, as last
amended by Regulation (EU) 2015/1761) is not considered necessary.
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